BR112017000320B1 - Uso de uma composição compreendendo um polímero de ácido nucleico fosforotioado e um análogo de nucleosídeo/nucleotídeo que inibe a hbv polimerase - Google Patents

Uso de uma composição compreendendo um polímero de ácido nucleico fosforotioado e um análogo de nucleosídeo/nucleotídeo que inibe a hbv polimerase Download PDF

Info

Publication number
BR112017000320B1
BR112017000320B1 BR112017000320-1A BR112017000320A BR112017000320B1 BR 112017000320 B1 BR112017000320 B1 BR 112017000320B1 BR 112017000320 A BR112017000320 A BR 112017000320A BR 112017000320 B1 BR112017000320 B1 BR 112017000320B1
Authority
BR
Brazil
Prior art keywords
hbv
nucleic acid
pharmaceutically acceptable
seq
infection
Prior art date
Application number
BR112017000320-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017000320A2 (pt
Inventor
Andrew Vaillant
Original Assignee
Replicor, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017000320(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor, Inc filed Critical Replicor, Inc
Publication of BR112017000320A2 publication Critical patent/BR112017000320A2/pt
Publication of BR112017000320B1 publication Critical patent/BR112017000320B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
BR112017000320-1A 2014-07-10 2015-07-07 Uso de uma composição compreendendo um polímero de ácido nucleico fosforotioado e um análogo de nucleosídeo/nucleotídeo que inibe a hbv polimerase BR112017000320B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US62/022,846 2014-07-10
US201462091943P 2014-12-15 2014-12-15
US62/091,943 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (2)

Publication Number Publication Date
BR112017000320A2 BR112017000320A2 (pt) 2017-11-07
BR112017000320B1 true BR112017000320B1 (pt) 2023-02-07

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000320-1A BR112017000320B1 (pt) 2014-07-10 2015-07-07 Uso de uma composição compreendendo um polímero de ácido nucleico fosforotioado e um análogo de nucleosídeo/nucleotídeo que inibe a hbv polimerase

Country Status (33)

Country Link
US (1) US9603865B2 (enExample)
EP (1) EP3166615B1 (enExample)
JP (2) JP2017521433A (enExample)
KR (2) KR20170029577A (enExample)
CN (2) CN106659730A (enExample)
AU (1) AU2015286199B2 (enExample)
BR (1) BR112017000320B1 (enExample)
CA (1) CA2954182C (enExample)
CL (1) CL2017000008A1 (enExample)
CU (1) CU20170001A7 (enExample)
DK (1) DK3166615T3 (enExample)
DO (1) DOP2017000002A (enExample)
EA (1) EA036745B1 (enExample)
EC (1) ECSP16097355A (enExample)
ES (1) ES2963814T3 (enExample)
FI (1) FI3166615T3 (enExample)
HK (1) HK1231402A1 (enExample)
HR (1) HRP20231400T1 (enExample)
HU (1) HUE064449T2 (enExample)
IL (1) IL249660B (enExample)
LT (1) LT3166615T (enExample)
MD (1) MD4760C8 (enExample)
MX (1) MX381042B (enExample)
MY (1) MY178087A (enExample)
PH (1) PH12017500010B1 (enExample)
PL (1) PL3166615T3 (enExample)
PT (1) PT3166615T (enExample)
RS (1) RS64833B1 (enExample)
SG (1) SG11201700073PA (enExample)
SI (1) SI3166615T1 (enExample)
SM (1) SMT202300380T1 (enExample)
TW (1) TWI766831B (enExample)
WO (1) WO2016004525A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2020097342A1 (en) * 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN113620993A (zh) * 2020-05-07 2021-11-09 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦d晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
US20220160748A1 (en) * 2020-11-20 2022-05-26 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
JP2024527380A (ja) 2021-07-09 2024-07-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド 腎機能障害を有する個体へのオリゴヌクレオチドの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
AU2003267785C1 (en) 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
SG187165A1 (en) 2010-08-20 2013-02-28 Replicor Inc Oligonucleotide chelate complexes
DK2632472T3 (en) * 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
AU2013262416B2 (en) * 2012-05-18 2017-05-11 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
NZ705730A (en) * 2012-08-30 2016-06-24 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
CN106659730A (zh) 2017-05-10
HRP20231400T1 (hr) 2024-02-16
MD4760C8 (ro) 2022-02-28
EP3166615A1 (en) 2017-05-17
JP6922030B2 (ja) 2021-08-18
US9603865B2 (en) 2017-03-28
ES2963814T3 (es) 2024-04-02
TWI766831B (zh) 2022-06-11
FI3166615T3 (fi) 2023-11-06
SI3166615T1 (sl) 2023-12-29
MX381042B (es) 2025-03-12
KR20170029577A (ko) 2017-03-15
AU2015286199B2 (en) 2020-05-14
BR112017000320A2 (pt) 2017-11-07
HUE064449T2 (hu) 2024-03-28
KR102734495B1 (ko) 2024-11-25
MX2017000053A (es) 2017-05-01
EA036745B1 (ru) 2020-12-16
HK1231402A1 (zh) 2017-12-22
MY178087A (en) 2020-10-02
JP2020143065A (ja) 2020-09-10
CN113750112A (zh) 2021-12-07
CA2954182C (en) 2023-08-15
EP3166615B1 (en) 2023-08-09
RS64833B1 (sr) 2023-12-29
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
SMT202300380T1 (it) 2024-01-10
PH12017500010A1 (en) 2017-05-15
SG11201700073PA (en) 2017-02-27
EA201790160A1 (ru) 2017-06-30
NZ727583A (en) 2024-08-30
MD20170014A2 (ro) 2017-07-31
IL249660A0 (en) 2017-02-28
TW201613617A (en) 2016-04-16
CA2954182A1 (en) 2016-01-14
PH12017500010B1 (en) 2022-07-29
US20160008393A1 (en) 2016-01-14
DOP2017000002A (es) 2017-03-15
JP2017521433A (ja) 2017-08-03
PT3166615T (pt) 2023-11-13
LT3166615T (lt) 2024-01-25
KR20230070330A (ko) 2023-05-22
DK3166615T3 (da) 2023-11-13
EP3166615A4 (en) 2018-01-17
CL2017000008A1 (es) 2017-06-09
AU2015286199A1 (en) 2017-02-23
PL3166615T3 (pl) 2024-02-19
MD4760B1 (ro) 2021-07-31
ECSP16097355A (es) 2017-03-31
WO2016004525A1 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
BR112017000320B1 (pt) Uso de uma composição compreendendo um polímero de ácido nucleico fosforotioado e um análogo de nucleosídeo/nucleotídeo que inibe a hbv polimerase
KR102918289B1 (ko) B형 간염 바이러스 (HBV) dsRNA 제제 조성물 및 이의 사용 방법
KR20120095397A (ko) Ｈｂｖ 안티센스 억제제
US20180179542A1 (en) OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA
BR112021015361A2 (pt) Agentes de rnai para a infecção pelo vírus da hepatite b
CN114507663A (zh) 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
WO2022022158A1 (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
TWI917310B (zh) Ｂ型肝炎病毒（ＨＢＶ）ｄｓＲＮＡ劑組合物及其使用方法
TW202606753A (zh) 一種核酸或核酸組合及其在製備治療乙肝的藥物中的應用
WO2025247242A1 (zh) 一种核酸或核酸组合及其在制备治疗乙肝的药物中的应用
OA21432A (en) Hepatitis b virus (HBV) dsRNA agent compositions and methods of use thereof.
HK40046664A (en) Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
HK1210022A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/07/2015, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2840 DE 10-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.